Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$3.46 -9.4%	$2.85	$2.00 ▼ $5.00	$16.12M	2.2	7.18 million shs	164,851 shs
BCEL Atreca	$0.09	$0.09	$0.05 ▼ $1.20	$3.57M	1.03	4.61 million shs	N/A
CTXR Citius Pharmaceuticals	$1.33 +1.5%	$1.42	$0.65 ▼ $17.00	$14.14M	1.19	326,514 shs	162,707 shs
NEUP Neuphoria Therapeutics	$8.10	$7.42	$2.12 ▼ $12.55	$15.23M	0.53	38,656 shs	36,924 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	0.00%	+8.81%	+23.57%	+27.25%	-4.62%
BCEL Atreca	0.00%	0.00%	0.00%	0.00%	0.00%
CTXR Citius Pharmaceuticals	0.00%	+8.13%	-16.61%	+56.77%	-90.98%
NEUP Neuphoria Therapeutics	0.00%	+9.02%	+8.14%	+64.63%	+809,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	0.5839 of 5 stars	0.0	3.0	0.0	0.0	2.3	1.7	0.0
BCEL Atreca	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	2.8768 of 5 stars	3.3	4.0	0.0	0.0	2.2	0.8	1.3
NEUP Neuphoria Therapeutics	2.313 of 5 stars	3.5	0.0	0.0	0.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	0.00	N/A	N/A	N/A
BCEL Atreca	0.00	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,884.96% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	159.26% Upside

Current Analyst Ratings Breakdown

Latest BCEL, NEUP, CTXR, and AIMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	806.18	N/A	N/A	$2.46 per share	1.41
BCEL Atreca	N/A	N/A	N/A	N/A	$2.01 per share	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$6.35 per share	N/A
NEUP Neuphoria Therapeutics	$15.66M	0.97	N/A	N/A	$15.85 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$4.99	N/A	∞	N/A	N/A	-108.25%	-56.94%	8/18/2025 (Estimated)
BCEL Atreca	-$97.16M	-$2.50	N/A	N/A	N/A	N/A	-157.90%	-71.39%	N/A
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.06	N/A	N/A	-60.03%	-33.83%	N/A
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/29/2025 (Estimated)

Latest BCEL, NEUP, CTXR, and AIMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AIMD Ainos	N/A	-$0.99	N/A	-$0.99	N/A	N/A
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
5/20/2025	Q3 2025	NEUP Neuphoria Therapeutics	-$0.47	$6.55	+$7.02	$6.55	N/A	$15.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
BCEL Atreca	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.96	2.88	1.91
BCEL Atreca	N/A	1.58	1.58
CTXR Citius Pharmaceuticals	N/A	0.47	0.06
NEUP Neuphoria Therapeutics	N/A	11.01	11.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
BCEL Atreca	37.47%
CTXR Citius Pharmaceuticals	16.88%
NEUP Neuphoria Therapeutics	15.90%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
BCEL Atreca	11.30%
CTXR Citius Pharmaceuticals	10.70%
NEUP Neuphoria Therapeutics	0.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	4.66 million	4.17 million	Not Optionable
BCEL Atreca	130	39.62 million	35.15 million	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A

BCEL, NEUP, CTXR, and AIMD Headlines

Recent News About These Companies

Dementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight

July 17, 2025 | finance.yahoo.com

NEUP Neuphoria Therapeutics Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Neuphoria Therapeutics Inc. (NEUP) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025 | globenewswire.com

Neuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business Updates

May 21, 2025 | finanznachrichten.de

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025 | globenewswire.com

Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Neuphoria Therapeutics provides review of 2024, highlights 2025 plans

April 16, 2025 | markets.businessinsider.com

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

April 15, 2025 | globenewswire.com

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

March 3, 2025 | globenewswire.com

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

February 12, 2025 | globenewswire.com

Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

February 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCEL, NEUP, CTXR, and AIMD Company Descriptions

Ainos NASDAQ:AIMD

$3.46 -0.36 (-9.42%)

As of 08/15/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Citius Pharmaceuticals NASDAQ:CTXR

$1.33 +0.02 (+1.53%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.34 +0.01 (+1.13%)

As of 08/15/2025 07:46 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Neuphoria Therapeutics NASDAQ:NEUP

$8.10 0.00 (0.00%)

As of 08/15/2025 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time